MedPath

Linezolid

Generic Name
Linezolid
Brand Names
Zyvox, Zyvoxam
Drug Type
Small Molecule
Chemical Formula
C16H20FN3O4
CAS Number
165800-03-3
Unique Ingredient Identifier
ISQ9I6J12J
Background

Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.

Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.

Indication

Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant Enterococcus faecium infections. Examples of susceptible bacteria include Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae.

Linezolid is not indicated for the treatment of Gram-negative infections, nor has it been evaluated for use longer than 28 days.

Associated Conditions
Community Acquired Pneumonia (CAP) caused by Staphylococcus Aureus Infections, Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Complicated Skin and Skin Structure Infection caused by Staphylococcus Aureus Infections, Complicated Skin and Skin Structure Infection caused by Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Infection caused by Streptococcus Pyogenes Infection, Nosocomial Pneumonia caused by Staphylococcus Aureus Infections, Nosocomial Pneumonia caused by Streptococcus Pneumoniae Infections, Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus Aureus Infections, Uncomplicated Skin and Skin Structure Infections caused by Streptococcus Pyogenes Infection, Vancomycin-resistant Enterococcus faecium infection
Clinical Trials
Related News

Continuous Infusion of Linezolid Versus Intermittent Dosing in the Treatment of Nosocomial Pneumonia

First Posted Date
2020-08-28
Last Posted Date
2021-09-16
Lead Sponsor
October 6 University
Target Recruit Count
169
Registration Number
NCT04531332
Locations
🇪🇬

Beni-suef University, Banī Suwayf, Egypt

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

First Posted Date
2020-03-17
Last Posted Date
2024-12-11
Lead Sponsor
The University of Queensland
Target Recruit Count
300
Registration Number
NCT04310930
Locations
🇦🇺

St George Hospital, Kogarah, New South Wales, Australia

🇦🇺

Austin Hospital, Heidelberg, Victoria, Australia

🇦🇺

Royal Melbourne Hospital, Parkville, Victoria, Australia

and more 47 locations

Economic Evaluation of New MDR TB Regimens

Phase 2
Completed
Conditions
Multi-drug Resistant Tuberculosis
Extensively Drug-Resistant Tuberculosis
Pulmonary Tuberculoses
Interventions
Drug: Standard Drugs
First Posted Date
2019-12-20
Last Posted Date
2024-04-22
Lead Sponsor
Medecins Sans Frontieres, Netherlands
Target Recruit Count
73
Registration Number
NCT04207112
Locations
🇿🇦

THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa

🇿🇦

King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa

🇧🇾

Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus

and more 4 locations

Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)

Conditions
Therapeutic Drug Monitoring
Subarachnoid Hemorrhage
Intracerebral Hemorrhage
First Posted Date
2019-10-18
Last Posted Date
2021-07-21
Lead Sponsor
Azienda Sanitaria-Universitaria Integrata di Udine
Target Recruit Count
104
Registration Number
NCT04132115
Locations
🇮🇹

Anesthesiology and Intensive Care Clinic - Department of Medicine - ASUIUD, Udine, Italy

🇮🇹

Terapia Intensiva 1, Udine, Italy

PRACTECAL-PKPD Sub Study

Phase 2
Conditions
Multi-drug Resistant Tuberculosis
Extensively Drug-Resistant Tuberculosis
Pulmonary Tuberculosis
Interventions
First Posted Date
2019-09-09
Last Posted Date
2021-05-14
Lead Sponsor
Medecins Sans Frontieres, Netherlands
Target Recruit Count
240
Registration Number
NCT04081077
Locations
🇧🇾

Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus

🇿🇦

King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa

🇿🇦

THINK Clinical Trial Unit, Hillcrest, Durban, KwaZulu-Natal, South Africa

and more 2 locations

Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

Phase 3
Completed
Conditions
Tuberculosis
Pre-XDR-TB
Extensively Drug-Resistant Tuberculosis
Multi Drug Resistant Tuberculosis
Rifampicin Resistant Tuberculosis
Interventions
First Posted Date
2019-08-20
Last Posted Date
2024-08-28
Lead Sponsor
Wits Health Consortium (Pty) Ltd
Target Recruit Count
402
Registration Number
NCT04062201
Locations
🇿🇦

Jose Pearson TB Hospital, Port Elizabeth, Eastern Cape, South Africa

🇿🇦

King DinuZulu Hospital Complex, Durban, KwaZulu Natal, South Africa

Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections

Phase 3
Terminated
Conditions
Surgical Site Infection
Interventions
Drug: Piperacillin/Tazobactam
First Posted Date
2019-08-01
Last Posted Date
2022-02-02
Lead Sponsor
Menarini Group
Target Recruit Count
268
Registration Number
NCT04042077
Locations
🇮🇹

Hospital Agostino Gemelli, Roma, Italy

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

Completed
Conditions
Multidrug Resistant Tuberculosis
Interventions
Drug: Directly observed therapy (DOT)
First Posted Date
2019-05-08
Last Posted Date
2024-05-29
Lead Sponsor
Medecins Sans Frontieres, Netherlands
Target Recruit Count
137
Registration Number
NCT03942354
Locations
🇧🇾

Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus

🇺🇿

Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital, Tashkent, Uzbekistan

🇿🇦

Helen Jospeh Hospital, Johannesburg, South Africa

and more 3 locations

Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM

Phase 2
Completed
Conditions
Tuberculosis Meningitis
HIV-1-infection
Interventions
Drug: Standard of Care anti-tuberculous therapy
First Posted Date
2019-04-25
Last Posted Date
2021-09-28
Lead Sponsor
University of Cape Town
Target Recruit Count
52
Registration Number
NCT03927313
Locations
🇿🇦

Mitchells Plain Hospital, Cape Town, Western Cape, South Africa

🇿🇦

Livingstone Hospital, Port Elizabeth, Eastern Cape, South Africa

🇿🇦

New Somerset Hospital, Cape Town, Western Cape, South Africa

and more 1 locations

Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis

Conditions
Tuberculous Meningitis
Interventions
First Posted Date
2019-04-02
Last Posted Date
2019-04-02
Lead Sponsor
Huashan Hospital
Target Recruit Count
150
Registration Number
NCT03898635
Locations
🇨🇳

Infectious department of Huashan Hospital, Fudan University, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy